NY-PAIGE
24.3.2022 08:32:08 CET | Business Wire | Press release
Paige , the global leader in AI-based diagnostic software in pathology, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review*. The product was unveiled at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 19-24, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006217/en/
Determining whether cancer in the breast has spread to the lymphatic system is critical to a patient’s diagnosis and planned treatment. Due to the size of the tissue area and size of the small micro-metastases, a pathologist’s accurate assessment of a lymph node slide can be tedious and time-consuming.
Designed to increase the accuracy and efficiency in the detection of breast cancer metastases that are most at-risk for being missed, Paige Breast Lymph Node leverages AI to empower pathologists to identify tumor metastases of any size, including small micrometastases, more efficiently and reliably. It is designed to enhance diagnostic accuracy for the most subtle metastatic foci and has over 98% slide level sensitivity to detect metastases of any size. A positive indication of metastatic breast cancer will be displayed at the individual lymph node level with Paige’s proprietary TissueMap, which highlights all regions on a slide that are suspicious for cancer. In addition, both slides and cases with suspected positive lymph nodes are highlighted, facilitating their prioritization and efficient review by the pathologist.
“Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious, manual task for pathologists,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “Paige Breast Lymph Node offers pathologists a quicker and more efficient way to analyze large quantities of lymph node tissue, as well as peace of mind for them and their patients.”
Paige Breast Lymph Node will be available immediately as part of the Paige Breast Suite. This software uses the same underlying AI technology as Paige Prostate, which can work with a broad range of data, staining techniques, and scanning artifacts, resulting in a generalizable AI that can be quickly deployed in a variety of laboratory and hospital settings.
“Paige Breast Lymph Node bolsters the value of the Paige Breast Suite to clinical pathologists,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “This product launch is an important step in our overall commercialization strategy as we bring the power of our AI platform to new disease areas. Alongside our FDA-approved Paige Prostate, the generalizability of the AI further validates the broader use of Paige’s software in assisting pathologist to diagnose cancer.”
Paige will host a webinar on March 30 to demonstrate how Paige Breast Lymph Node can be used in clinical practice. For more information about Paige Breast Lymph Node, visit http://info.paige.ai/breast or contact info@paige.ai .
*Paige Breast Lymph Node is available for research use only in United States and in other regions where research use is permitted. Research use only products should not be used in diagnostic procedures.
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.
For additional information, please visit: https://www.paige.ai , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006217/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HOF Capital Completes €1 Billion Acquisition of Porsche’s Stakes in Bugatti Rimac and Rimac Group9.9.2026 18:00:00 CEST | Press release
HOF Capital today announced the completion of its acquisition of Porsche’s equity interests in Bugatti Rimac and Rimac Group through an HOF-led consortium. The transaction, first announced in April 2026, closed following the satisfaction of all conditions, including regulatory clearances. Porsche’s combined interests were valued at approximately €1 billion. HOF Capital originated and led the transaction, assembling a consortium of institutional investors from the United States and Europe. Following completion of the transaction, HOF holds a 23.5% stake and becomes the largest shareholder in Rimac Group, which holds the 55% controlling interest in Bugatti Rimac. HOF and its consortium also acquired Porsche’s direct 45% interest in Bugatti Rimac. As part of the investment, HOF Capital holds three supervisory board seats across Rimac Group and Bugatti Rimac. Hisham Elhaddad, Co-Founder and Managing Partner of HOF Capital, has joined the Supervisory Boards of both Bugatti Rimac and Rimac G
The Rock-It Company Expands Dynamic Dox to Provide ATA Carnet Services Across the US and Canada9.9.2026 17:00:00 CEST | Press release
Expansion provides access and expert ATA Carnet services for customers across new regions The Rock-It Company announced today the expansion of Dynamic Dox, the industry-leading provider of ATA Carnets, to now service partners and projects based in the United States, Canada and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909137375/en/ Following over a decade of expertise and leading service across the United Kingdom since 2014, Dynamic Dox will now provide new regions with dedicated document preparation for time-sensitive logistics projects, and urgent ATA Carnets for international shipments and critical business travel needs. The news of the expansion follows Dynamic Dox’s recent brand refresh, introducing an updated identity and connection to The Rock-It Company as Dynamic Dox By Rock-It. The expansion is led by Amanda Barlow, VP of Global ATA Carnets at The Rock-It Company, who has helped to drive the platfor
Ennov Appoints Oxana Pickeral as Chief Executive Officer9.9.2026 16:00:00 CEST | Press release
Ennov (the “Company”), a global provider of a unified compliance platform that streamlines regulatory, clinical, quality, and pharmacovigilance operations for life sciences and healthcare companies, today announced the appointment of Dr. Oxana Pickeral as Chief Executive Officer. Founder and outgoing CEO, Olivier Pâris, will join Ennov’s Board of Directors and continue to support the company as a Strategic Advisor. Dr. Pickeral has spent her career at the forefront of innovation in life sciences technology, from her early work on the Human Genome Project to growing Amazon Web Services’ Healthcare & Life Sciences partner business, enabling modern cloud solutions across the industry. She joins Ennov most recently from Honeywell, where she served as Global Software and Connected Life Sciences business leader, and previously as President and CEO of Sparta Systems, a Honeywell company. Across her leadership roles, she has successfully scaled global companies at the intersection of life scie
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom